Review




Structured Review

Haematologic Technologies human purified plasma-derived fibronectin
Plasma and recombinant VWF bind to <t>fibronectin.</t> Human fibronectin was captured on a plate and used to bind plasma VWF (healthy controls or subjects with type 3 VWD) or recombinant VWF. Decreased binding was noted for VWF constructs unable to form multimeric structures (2773R and 87S) as well as constructs with VWF A1 domain variants (1392A, 1395A, 1399H). Results are graphed as a ratio of VWF bound to fibrinogen over VWF antigen to account for minor differences in total protein. Error bars show 1 standard deviation. Results are average of ≥3 experiments. * signifies P <.05 and ** signifies P <.02 (plasma samples compared against each other, recombinant samples compared to WT recombinant VWF). VWD, von Willebrand disease; VWF, von Willebrand factor; VWF:Ag, von Willebrand factor antigen; WT, wild‐type
Human Purified Plasma Derived Fibronectin, supplied by Haematologic Technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human purified plasma-derived fibronectin/product/Haematologic Technologies
Average 90 stars, based on 1 article reviews
human purified plasma-derived fibronectin - by Bioz Stars, 2026-03
90/100 stars

Images

1) Product Images from "Fibronectin binding to von Willebrand factor occurs via the A1 domain"

Article Title: Fibronectin binding to von Willebrand factor occurs via the A1 domain

Journal: Research and Practice in Thrombosis and Haemostasis

doi: 10.1002/rth2.12534

Plasma and recombinant VWF bind to fibronectin. Human fibronectin was captured on a plate and used to bind plasma VWF (healthy controls or subjects with type 3 VWD) or recombinant VWF. Decreased binding was noted for VWF constructs unable to form multimeric structures (2773R and 87S) as well as constructs with VWF A1 domain variants (1392A, 1395A, 1399H). Results are graphed as a ratio of VWF bound to fibrinogen over VWF antigen to account for minor differences in total protein. Error bars show 1 standard deviation. Results are average of ≥3 experiments. * signifies P <.05 and ** signifies P <.02 (plasma samples compared against each other, recombinant samples compared to WT recombinant VWF). VWD, von Willebrand disease; VWF, von Willebrand factor; VWF:Ag, von Willebrand factor antigen; WT, wild‐type
Figure Legend Snippet: Plasma and recombinant VWF bind to fibronectin. Human fibronectin was captured on a plate and used to bind plasma VWF (healthy controls or subjects with type 3 VWD) or recombinant VWF. Decreased binding was noted for VWF constructs unable to form multimeric structures (2773R and 87S) as well as constructs with VWF A1 domain variants (1392A, 1395A, 1399H). Results are graphed as a ratio of VWF bound to fibrinogen over VWF antigen to account for minor differences in total protein. Error bars show 1 standard deviation. Results are average of ≥3 experiments. * signifies P <.05 and ** signifies P <.02 (plasma samples compared against each other, recombinant samples compared to WT recombinant VWF). VWD, von Willebrand disease; VWF, von Willebrand factor; VWF:Ag, von Willebrand factor antigen; WT, wild‐type

Techniques Used: Clinical Proteomics, Recombinant, Binding Assay, Construct, Standard Deviation

Fibronectin preferentially interacts with higher‐molecular‐weight VWF multimers. Binding of VWF to human fibronectin is shown using purified preparations of recombinant ultra‐high‐molecular‐weight VWF multimers (ultra), high‐molecular‐weight VWF multimers (high), medium‐molecular‐weight VWF multimers (medium), and low‐molecular‐weight VWF multimers (low). Results are graphed as a fraction of WT recombinant VWF binding with all multimers present to normalize for the total amount of VWF present in each preparation. Error bars show 1 standard deviation. Results are average of ≥3 experiments. VWF, von Willebrand factor; VWF:Ag, von Willebrand factor antigen; WT, wild‐type
Figure Legend Snippet: Fibronectin preferentially interacts with higher‐molecular‐weight VWF multimers. Binding of VWF to human fibronectin is shown using purified preparations of recombinant ultra‐high‐molecular‐weight VWF multimers (ultra), high‐molecular‐weight VWF multimers (high), medium‐molecular‐weight VWF multimers (medium), and low‐molecular‐weight VWF multimers (low). Results are graphed as a fraction of WT recombinant VWF binding with all multimers present to normalize for the total amount of VWF present in each preparation. Error bars show 1 standard deviation. Results are average of ≥3 experiments. VWF, von Willebrand factor; VWF:Ag, von Willebrand factor antigen; WT, wild‐type

Techniques Used: Molecular Weight, Binding Assay, Purification, Recombinant, High Molecular Weight, Standard Deviation

Inhibition of VWF‐fibronectin interactions. VWF binding to human fibronectin was measured alone (WT), and in the presence of anti‐VWF antibody AVW‐3, which blocks the A1 domain (anti‐VWF A1), a polyclonal VWF antibody (polyclonal anti‐VWF), collagen type III and IV, and extracellular matrix proteins thrombospondin, vitronectin, and laminin. Results are graphed as a percent of WT VWF bound to fibronectin in the absence of antibody. Error bars show 1 standard deviation. Results are average of three or more experiments. ** signifies P < .01. ECM, extracellular matrix; VWF, von Willebrand factor; VWF:Ag, von Willebrand factor antigen; WT, wild‐type
Figure Legend Snippet: Inhibition of VWF‐fibronectin interactions. VWF binding to human fibronectin was measured alone (WT), and in the presence of anti‐VWF antibody AVW‐3, which blocks the A1 domain (anti‐VWF A1), a polyclonal VWF antibody (polyclonal anti‐VWF), collagen type III and IV, and extracellular matrix proteins thrombospondin, vitronectin, and laminin. Results are graphed as a percent of WT VWF bound to fibronectin in the absence of antibody. Error bars show 1 standard deviation. Results are average of three or more experiments. ** signifies P < .01. ECM, extracellular matrix; VWF, von Willebrand factor; VWF:Ag, von Willebrand factor antigen; WT, wild‐type

Techniques Used: Inhibition, Binding Assay, Standard Deviation

Binding affinities of VWF for collagen IV and  fibronectin
Figure Legend Snippet: Binding affinities of VWF for collagen IV and fibronectin

Techniques Used: Binding Assay, Concentration Assay

VWF binding to fibronectin and collagen IV. VWF binding to human fibronectin (black) and human collagen IV (gray) was measured using the Octet Biosensor to determine binding affinities. The x axis shows varying VWF concentrations from 0 to 3 μg/mL, and the y axis shows the K D in nM. K D , dissociation constant; VWF, von Willebrand factor
Figure Legend Snippet: VWF binding to fibronectin and collagen IV. VWF binding to human fibronectin (black) and human collagen IV (gray) was measured using the Octet Biosensor to determine binding affinities. The x axis shows varying VWF concentrations from 0 to 3 μg/mL, and the y axis shows the K D in nM. K D , dissociation constant; VWF, von Willebrand factor

Techniques Used: Binding Assay



Similar Products

90
Haematologic Technologies human purified plasma-derived fibronectin
Plasma and recombinant VWF bind to <t>fibronectin.</t> Human fibronectin was captured on a plate and used to bind plasma VWF (healthy controls or subjects with type 3 VWD) or recombinant VWF. Decreased binding was noted for VWF constructs unable to form multimeric structures (2773R and 87S) as well as constructs with VWF A1 domain variants (1392A, 1395A, 1399H). Results are graphed as a ratio of VWF bound to fibrinogen over VWF antigen to account for minor differences in total protein. Error bars show 1 standard deviation. Results are average of ≥3 experiments. * signifies P <.05 and ** signifies P <.02 (plasma samples compared against each other, recombinant samples compared to WT recombinant VWF). VWD, von Willebrand disease; VWF, von Willebrand factor; VWF:Ag, von Willebrand factor antigen; WT, wild‐type
Human Purified Plasma Derived Fibronectin, supplied by Haematologic Technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/human purified plasma-derived fibronectin/product/Haematologic Technologies
Average 90 stars, based on 1 article reviews
human purified plasma-derived fibronectin - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

90
Fisher Scientific purified fibronectin derived human plasma
Plasma and recombinant VWF bind to <t>fibronectin.</t> Human fibronectin was captured on a plate and used to bind plasma VWF (healthy controls or subjects with type 3 VWD) or recombinant VWF. Decreased binding was noted for VWF constructs unable to form multimeric structures (2773R and 87S) as well as constructs with VWF A1 domain variants (1392A, 1395A, 1399H). Results are graphed as a ratio of VWF bound to fibrinogen over VWF antigen to account for minor differences in total protein. Error bars show 1 standard deviation. Results are average of ≥3 experiments. * signifies P <.05 and ** signifies P <.02 (plasma samples compared against each other, recombinant samples compared to WT recombinant VWF). VWD, von Willebrand disease; VWF, von Willebrand factor; VWF:Ag, von Willebrand factor antigen; WT, wild‐type
Purified Fibronectin Derived Human Plasma, supplied by Fisher Scientific, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/purified fibronectin derived human plasma/product/Fisher Scientific
Average 90 stars, based on 1 article reviews
purified fibronectin derived human plasma - by Bioz Stars, 2026-03
90/100 stars
  Buy from Supplier

Image Search Results


Plasma and recombinant VWF bind to fibronectin. Human fibronectin was captured on a plate and used to bind plasma VWF (healthy controls or subjects with type 3 VWD) or recombinant VWF. Decreased binding was noted for VWF constructs unable to form multimeric structures (2773R and 87S) as well as constructs with VWF A1 domain variants (1392A, 1395A, 1399H). Results are graphed as a ratio of VWF bound to fibrinogen over VWF antigen to account for minor differences in total protein. Error bars show 1 standard deviation. Results are average of ≥3 experiments. * signifies P <.05 and ** signifies P <.02 (plasma samples compared against each other, recombinant samples compared to WT recombinant VWF). VWD, von Willebrand disease; VWF, von Willebrand factor; VWF:Ag, von Willebrand factor antigen; WT, wild‐type

Journal: Research and Practice in Thrombosis and Haemostasis

Article Title: Fibronectin binding to von Willebrand factor occurs via the A1 domain

doi: 10.1002/rth2.12534

Figure Lengend Snippet: Plasma and recombinant VWF bind to fibronectin. Human fibronectin was captured on a plate and used to bind plasma VWF (healthy controls or subjects with type 3 VWD) or recombinant VWF. Decreased binding was noted for VWF constructs unable to form multimeric structures (2773R and 87S) as well as constructs with VWF A1 domain variants (1392A, 1395A, 1399H). Results are graphed as a ratio of VWF bound to fibrinogen over VWF antigen to account for minor differences in total protein. Error bars show 1 standard deviation. Results are average of ≥3 experiments. * signifies P <.05 and ** signifies P <.02 (plasma samples compared against each other, recombinant samples compared to WT recombinant VWF). VWD, von Willebrand disease; VWF, von Willebrand factor; VWF:Ag, von Willebrand factor antigen; WT, wild‐type

Article Snippet: Amine binding maleic anhydride plates (Thermo Fisher Scientific, Waltham, MA, USA) were coated at 1 μg/mL with human purified plasma‐derived fibronectin (Haematologic Technologies, Inc., Essex Junction, VT, USA) diluted in phosphate‐buffered saline (PBS; pH 7.4) and incubated at 2 to 4°C overnight.

Techniques: Clinical Proteomics, Recombinant, Binding Assay, Construct, Standard Deviation

Fibronectin preferentially interacts with higher‐molecular‐weight VWF multimers. Binding of VWF to human fibronectin is shown using purified preparations of recombinant ultra‐high‐molecular‐weight VWF multimers (ultra), high‐molecular‐weight VWF multimers (high), medium‐molecular‐weight VWF multimers (medium), and low‐molecular‐weight VWF multimers (low). Results are graphed as a fraction of WT recombinant VWF binding with all multimers present to normalize for the total amount of VWF present in each preparation. Error bars show 1 standard deviation. Results are average of ≥3 experiments. VWF, von Willebrand factor; VWF:Ag, von Willebrand factor antigen; WT, wild‐type

Journal: Research and Practice in Thrombosis and Haemostasis

Article Title: Fibronectin binding to von Willebrand factor occurs via the A1 domain

doi: 10.1002/rth2.12534

Figure Lengend Snippet: Fibronectin preferentially interacts with higher‐molecular‐weight VWF multimers. Binding of VWF to human fibronectin is shown using purified preparations of recombinant ultra‐high‐molecular‐weight VWF multimers (ultra), high‐molecular‐weight VWF multimers (high), medium‐molecular‐weight VWF multimers (medium), and low‐molecular‐weight VWF multimers (low). Results are graphed as a fraction of WT recombinant VWF binding with all multimers present to normalize for the total amount of VWF present in each preparation. Error bars show 1 standard deviation. Results are average of ≥3 experiments. VWF, von Willebrand factor; VWF:Ag, von Willebrand factor antigen; WT, wild‐type

Article Snippet: Amine binding maleic anhydride plates (Thermo Fisher Scientific, Waltham, MA, USA) were coated at 1 μg/mL with human purified plasma‐derived fibronectin (Haematologic Technologies, Inc., Essex Junction, VT, USA) diluted in phosphate‐buffered saline (PBS; pH 7.4) and incubated at 2 to 4°C overnight.

Techniques: Molecular Weight, Binding Assay, Purification, Recombinant, High Molecular Weight, Standard Deviation

Inhibition of VWF‐fibronectin interactions. VWF binding to human fibronectin was measured alone (WT), and in the presence of anti‐VWF antibody AVW‐3, which blocks the A1 domain (anti‐VWF A1), a polyclonal VWF antibody (polyclonal anti‐VWF), collagen type III and IV, and extracellular matrix proteins thrombospondin, vitronectin, and laminin. Results are graphed as a percent of WT VWF bound to fibronectin in the absence of antibody. Error bars show 1 standard deviation. Results are average of three or more experiments. ** signifies P < .01. ECM, extracellular matrix; VWF, von Willebrand factor; VWF:Ag, von Willebrand factor antigen; WT, wild‐type

Journal: Research and Practice in Thrombosis and Haemostasis

Article Title: Fibronectin binding to von Willebrand factor occurs via the A1 domain

doi: 10.1002/rth2.12534

Figure Lengend Snippet: Inhibition of VWF‐fibronectin interactions. VWF binding to human fibronectin was measured alone (WT), and in the presence of anti‐VWF antibody AVW‐3, which blocks the A1 domain (anti‐VWF A1), a polyclonal VWF antibody (polyclonal anti‐VWF), collagen type III and IV, and extracellular matrix proteins thrombospondin, vitronectin, and laminin. Results are graphed as a percent of WT VWF bound to fibronectin in the absence of antibody. Error bars show 1 standard deviation. Results are average of three or more experiments. ** signifies P < .01. ECM, extracellular matrix; VWF, von Willebrand factor; VWF:Ag, von Willebrand factor antigen; WT, wild‐type

Article Snippet: Amine binding maleic anhydride plates (Thermo Fisher Scientific, Waltham, MA, USA) were coated at 1 μg/mL with human purified plasma‐derived fibronectin (Haematologic Technologies, Inc., Essex Junction, VT, USA) diluted in phosphate‐buffered saline (PBS; pH 7.4) and incubated at 2 to 4°C overnight.

Techniques: Inhibition, Binding Assay, Standard Deviation

Binding affinities of VWF for collagen IV and  fibronectin

Journal: Research and Practice in Thrombosis and Haemostasis

Article Title: Fibronectin binding to von Willebrand factor occurs via the A1 domain

doi: 10.1002/rth2.12534

Figure Lengend Snippet: Binding affinities of VWF for collagen IV and fibronectin

Article Snippet: Amine binding maleic anhydride plates (Thermo Fisher Scientific, Waltham, MA, USA) were coated at 1 μg/mL with human purified plasma‐derived fibronectin (Haematologic Technologies, Inc., Essex Junction, VT, USA) diluted in phosphate‐buffered saline (PBS; pH 7.4) and incubated at 2 to 4°C overnight.

Techniques: Binding Assay, Concentration Assay

VWF binding to fibronectin and collagen IV. VWF binding to human fibronectin (black) and human collagen IV (gray) was measured using the Octet Biosensor to determine binding affinities. The x axis shows varying VWF concentrations from 0 to 3 μg/mL, and the y axis shows the K D in nM. K D , dissociation constant; VWF, von Willebrand factor

Journal: Research and Practice in Thrombosis and Haemostasis

Article Title: Fibronectin binding to von Willebrand factor occurs via the A1 domain

doi: 10.1002/rth2.12534

Figure Lengend Snippet: VWF binding to fibronectin and collagen IV. VWF binding to human fibronectin (black) and human collagen IV (gray) was measured using the Octet Biosensor to determine binding affinities. The x axis shows varying VWF concentrations from 0 to 3 μg/mL, and the y axis shows the K D in nM. K D , dissociation constant; VWF, von Willebrand factor

Article Snippet: Amine binding maleic anhydride plates (Thermo Fisher Scientific, Waltham, MA, USA) were coated at 1 μg/mL with human purified plasma‐derived fibronectin (Haematologic Technologies, Inc., Essex Junction, VT, USA) diluted in phosphate‐buffered saline (PBS; pH 7.4) and incubated at 2 to 4°C overnight.

Techniques: Binding Assay